Articles cited in this Review were obtained through searches of Medline, meeting abstract databases, and reference lists from key reviews. Search terms included the names of TNF antagonists with one or more of the following: “mechanism”, “monocyte”, “macrophage”, “T cell”, “cytokine”, “lysis”, “apoptosis”, “granuloma”, “granulomatous”, “tuberculosis”, “histoplasmosis”, “coccidioidomycosis”, or “aspergillosis”. Priority was given to primary research publications. No date restrictions were
ReviewTumour necrosis factor antagonists: structure, function, and tuberculosis risks
Introduction
This year marks the tenth anniversary of the approvals of the first tumour necrosis factor (TNF)-alpha antagonists for the treatment of chronic inflammatory conditions. Two classes of antagonists, monoclonal antibody and soluble receptor, have proven to be highly effective treatments for rheumatoid arthritis, psoriasis, psoriatic arthritis, ankylosing spondylitis, and juvenile rheumatoid arthritis. However, as clinical experience with these drugs has grown, differences between them, regarding efficacy in granulomatous inflammatory conditions and risk of granulomatous infections—especially tuberculosis—have become apparent. Our understanding of this subject has continued to evolve since it was reviewed in 2003.1 This Review focuses on recent publications that elucidate the structure–function relation of the TNF blockers in the context of tuberculosis, and that inform tuberculosis prevention and management in this susceptible patient population.
Section snippets
TNF biology
Members of the TNF and TNF receptor (TNFR) superfamily are important regulators of immune cell proliferation, survival, differentiation, and apoptosis.2, 3, 4 TNF is first produced as a transmembrane protein (tmTNF), which then is cleaved by a metalloproteinase to a soluble form (sTNF).5, 6, 7 Biological activity results from the association of three monomers to form trimeric TNF, which then binds to cell-surface TNFR1 or TNFR2, leading to receptor oligomerisation.8, 9, 10
TNFR1 and TNFR2 have
TNF antagonists
There are currently three approved TNF monoclonal antibodies: infliximab, adalimumab, and certolizumab pegol (figure 1). Infliximab is a chimeric monoclonal antibody composed of a human IgG1 constant region and a murine variable region. Adalimumab is a humanised monoclonal antibody, with both human IgG1 constant and variable regions. Certolizumab pegol is a pegylated, humanised monoclonal anti-TNF Fab' (fragment, antigen binding) fragment. Infliximab and adalimumab are approved for the
TNF antagonists and granulomatous infections
Clinical studies of the effect of TNF antagonists on granulomatous infections face several distinct challenges. The rarity of these infections in North America or Europe has prevented their analysis as an endpoint in prospective randomised controlled clinical trials. A meta-analysis of pooled randomised placebo-controlled trials and extension studies of etanercept, for example, did not detect any effect of this treatment on tuberculosis compared with expected rates in these regions.46 This
Structural and functional insights into differential infection risks
Several structural and functional differences among the TNF antagonists could account for the differences in granulomatous infection risk.
Diagnosis and treatment of latent tuberculosis infection
Our understanding of the human tuberculosis risks of the TNF blockers largely reflects experience garnered in regions of low tuberculosis transmission. In the USA, for example, both the prevalence of latent tuberculosis infection and the annual risk of acquiring infection in the general population are low.96, 97 As a result, most tuberculosis cases are thought to arise from reactivation of latent infection acquired in high prevalence regions. Current strategies to minimise tuberculosis risks in
Management of incident tuberculosis cases
Many questions remain regarding optimum management of patients who develop tuberculosis as a consequence of TNF blockade. Most authorities recommend that anti-TNF therapy be halted in such cases until a response to antituberculosis therapy is evident, but clinical trials in this regard have not yet been done. A single case report describes the successful resumption of infliximab therapy after 2 months of tuberculosis treatment in a patient with peritoneal tuberculosis.118 A small clinical trial
Conclusions
The introduction of TNF antagonists into clinical medicine has greatly advanced the treatment of several chronic inflammatory diseases, but has also resulted in a greater clinical awareness of the risks these therapies pose for granulomatous infections. Several studies have confirmed the increased risk of granulomatous infections of TNF antibodies compared with soluble receptor, particularly with regard to reactivation of latent M tuberculosis infection, which for infliximab occurs at a monthly
Search strategy and selection criteria
References (125)
- et al.
Anti-tumour necrosis factor agents and tuberculosis risk: mechanisms of action and clinical management
Lancet Infect Dis
(2003) - et al.
Signal transduction by tumor necrosis factor and its relatives
Trends Cell Biol
(2001) - et al.
A novel form of TNF/cachectin is a cell surface cytotoxic transmembrane protein: ramifications for the complex physiology of TNF
Cell
(1988) - et al.
The structure of tumor necrosis factor-alpha at 2.6 A resolution. Implications for receptor binding
J Biol Chem
(1989) - et al.
Infliximab induces potent anti-inflammatory responses by outside-to-inside signals through transmembrane TNF-alpha
Gastroenterology
(2005) - et al.
Mice deficient for the 55 kd tumor necrosis factor receptor are resistant to endotoxic shock, yet succumb to L monocytogenes infection
Cell
(1993) - et al.
The transmembrane form of tumor necrosis factor is the prime activating ligand of the 80 kDa tumor necrosis factor receptor
Cell
(1995) Biological functions of tumor necrosis factor cytokines and their receptors
Cytokine Growth Factor Rev
(2003)- et al.
Tumor necrosis factor-alpha is required in the protective immune response against Mycobacterium tuberculosis in mice
Immunity
(1995) - et al.
Fatal Mycobacterium bovis BCG infection in TNF-LT-alpha-deficient mice
Clin Immunol
(2000)
Contribution of transmembrane tumor necrosis factor to host defense against Mycobacterium bovis bacillus Calmette-guerin and Mycobacterium tuberculosis infections
Am J Pathol
Membrane tumor necrosis factor confers partial protection to listeria infection
Am J Pathol
Effectiveness of infliximab in treating selected patients with sarcoidosis
Respir Med
Clinical pharmacokinetics of TNF antagonists: how do they differ?
Semin Arthritis Rheum
Etanercept for active Crohn's disease: a randomized, double-blind, placebo-controlled trial
Gastroenterology
Etanercept for the treatment of stage II and III progressive pulmonary sarcoidosis
Chest
Antirheumatic drugs and the risk of tuberculosis
J Infect Dis
The RATIO observatory: French registry of opportunistic infections, severe bacterial infections, and lymphomas complicating anti-TnFalpha therapy
Joint Bone Spine
Characterization of noncovalent complexes of recombinant human monoclonal antibody and antigen using cation exchange, size exclusion chromatography, and BIAcore
Anal Biochem
Chimeric anti-TNF-alpha monoclonal antibody cA2 binds recombinant transmembrane TNF-alpha and activates immune effector functions
Cytokine
Infliximab but not etanercept induces apoptosis in lamina propria T-lymphocytes from patients with Crohn's disease
Gastroenterology
Effect of different tumor necrosis factor (TNF) reactive agents on reverse signaling of membrane integrated TNF in monocytes
Cytokine
Etanercept induces apoptosis of dermal dendritic cells in psoriatic plaques of responding patients
J Am Acad Dermatol
Mechanisms of action of etanercept in psoriasis
J Investig Dermatol Symp Proc
Infliximab downregulates interferon-gamma production in activated gut T-lymphocytes from patients with Crohn's disease
Cytokine
Effects of etanercept are distinct from infliximab in modulating proinflammatory genes in activated human leukocytes
J Investig Dermatol Symp Proc
Tumor necrosis factor signaling
Cell Death Differ
The intriguing biology of the tumour necrosis factor/tumour necrosis factor receptor superfamily: players, rules and the games
Immunology
A metalloproteinase disintegrin that releases tumour-necrosis factor-alpha from cells
Nature
The 26-kD transmembrane form of tumor necrosis factor alpha on activated CD4+ T cell clones provides a costimulatory signal for human B cell activation
J Exp Med
Outside-to-inside signal through the membrane TNF-alpha induces E-selectin (CD62E) expression on activated human CD4+ T cells
J Immunol
TNF receptor-deficient mice reveal divergent roles for p55 and p75 in several models of inflammation
J Immunol
TNF regulates chemokine induction essential for cell recruitment, granuloma formation, and clearance of mycobacterial infection
J Immunol
Effects of tumor necrosis factor alpha on host immune response in chronic persistent tuberculosis: possible role for limiting pathology
Infect Immun
Structural deficiencies in granuloma formation in TNF gene-targeted mice underlie the heightened susceptibility to aerosol Mycobacterium tuberculosis infection, which is not compensated for by lymphotoxin
J Immunol
An essential role for interferon gamma in resistance to Mycobacterium tuberculosis infection
J Exp Med
Transmembrane TNF is sufficient to initiate cell migration and granuloma formation and provide acute, but not long-term, control of Mycobacterium tuberculosis infection
J Immunol
Decreased sensitivity to tumour-necrosis factor but normal T-cell development in TNF receptor-2-deficient mice
Nature
Susceptibility to Salmonella typhimurium infection and effectiveness of vaccination in mice deficient in the tumor necrosis factor alpha p55 receptor
Infect Immun
Mice lacking the tumour necrosis factor receptor 1 are resistant to TNF-mediated toxicity but highly susceptible to infection by Listeria monocytogenes
Nature
The lymphotoxin beta receptor is critically involved in controlling infections with the intracellular pathogens Mycobacterium tuberculosis and Listeria monocytogenes
J Immunol
Secreted lymphotoxin-alpha is essential for the control of an intracellular bacterial infection
J Exp Med
Differential effects of TNF and LTalpha in the host defense against M bovis BCG
Eur J Immunol
Transmembrane TNF induces an efficient cell-mediated immunity and resistance to Mycobacterium bovis bacillus Calmette-Guerin infection in the absence of secreted TNF and lymphotoxin-alpha
J Immunol
Transmembrane TNF protects mutant mice against intracellular bacterial infections, chronic inflammation and autoimmunity
Eur J Immunol
Differential requirements for soluble and transmembrane tumor necrosis factor in the immunological control of primary and secondary Listeria monocytogenes infection
Infect Immun
Humira prescribing information, 2007. Abbott Park, IL, USA: Abbott Laboratories
Infliximab (Remicade) prescribing information
Infliximab therapy in patients with chronic sarcoidosis and pulmonary involvement
Am J Respir Crit Care Med
A double-blinded, randomized, placebo-controlled trial of infliximab in subjects with active pulmonary sarcoidosis
Sarcoidosis Vasc Diffuse Lung Dis
Cited by (237)
Therapeutic host-directed strategies to improve outcome in tuberculosis
2020, Mucosal ImmunologyTumor Necrosis Factor Inhibitors
2020, Comprehensive Dermatologic Drug Therapy, Fourth EditionSafety of TNF inhibitors in rheumatic disease in case of NAFLD and cirrhosis
2020, Seminars in Arthritis and RheumatismCitation Excerpt :Among the TNFi, infliximab (a chimeric mab), adalimumab and golimumab (two humanized mabs), certolizumab pegol (a pegylated Fab fragment) and etanercept (a soluble receptor) are the available drugs for rheumatological indications. The main adverse effect of TNFi is an increased risk of infectious disease [2]. The use of these treatments should take into account comorbidity patterns of patients, such as infectious, neoplastic or cardiac history.
TNF in Human Tuberculosis: A Double-Edged Sword
2024, Immune NetworkIntestinal Inflammation and Regeneration–Interdigitating Processes Controlled by Dietary Lipids in Inflammatory Bowel Disease
2024, International Journal of Molecular Sciences